Protai Adds $12 Million to Seed Round
Israeli startup Protai has raised an additional $12 million in seed funding led in part by Grove Ventures, a leading Israeli early-stage venture capital firm, bringing its total seed round funding to $20 million. The company has developed an AI-powered drug discovery platform that focuses on proteomics, mapping diseases at the protein level. By leveraging this technology, Protai aims to improve patient response prediction to drugs and discover novel drug targets that genomic approaches may have overlooked. The company has established laboratories, recruited an experienced drug discovery team, and formed collaborations with leading hospitals to access well-defined samples for its comprehensive tumor mapping process. Protai’s goal is to revolutionize the drug development landscape by combining deep proteomics research with machine learning to better combat complex diseases and create a healthier world.
>> Click here to read the full article originally published in CTech by Calcalist: